Seeking Alpha
10 Aug 2026, 20:38 UTC · 12h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
AbCellera announced top-line results from the Phase II study of ABCL635 for the treatment of moderate-to-severe hot flashes. — Phase II results are critical milestones for biotech valuations as they determine the viability of a drug candidate for large-scale Phase III trials.
+0.60Which stocks this story touches
The company is presenting top-line results from a Phase II clinical trial, which is a key milestone for drug development.
Continue reading
6 related stories
Top 2 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Business Wire
1d ago
